<DOC>
	<DOCNO>NCT00881543</DOCNO>
	<brief_summary>The purpose study demonstrate secretion glucose , insulin , glucagon , C-peptide lipid profile isocaloric diet different nutritional compound ( fat , protein carbohydrate food ) drug näive tipo 2 patient .</brief_summary>
	<brief_title>`` Effect Dipeptidyl Peptidase IV After Diets näive Type 2 Diabetic Patients ''</brief_title>
	<detailed_description>It well know progressive deterioration beta-cell function time type 2 diabetes ( DM2 ) , indicate UKPDS ( United Kingdom Prospective Diabetes Study ) , regardless therapy allocation , albeit conventional ( mainly diet ) , insulin , chlorpropamide , glibenclamide metformin treatment . Moreover , pancreatic islet function find 50 % normal time diagnosis , independent degree insulin resistance , reduction function probably commence 10-12 year prior diagnosis aggravate increase fast plasma glucose level . Optimal metabolic control , especially early intensive glycemic control , play role prevention progressive beta cell dysfunction possibly destruction betacells worsen diabetes . Many report show induction normoglycemia DM2 result improve beta cell function insulin resistance.The major therapeutic drawback use native GLP-1 short half-life le 2 minute , follow exogenous administration , previously indicate due part protease DDP-IV result , prevent degradation native GLP-1 inhibit active DDP-IV enzyme emerge therapeutic strategy enhance endogenous GLP-1 action vivo.Considering , sitagliptin first FDA ANVISA authorize dipeptidyl peptidase-IV ( DPP-IV ) inhibitor diabetes treatment consider lack data DPP-IV inhibitor effect glucose , glucagon , insulin , C -peptide fat isocaloric diet different nutritional composition drug näive patient type 2 diabetes , design study .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Drug näive patient T2DM ( purpose study `` drug näive '' patient define subject never treat oral antidiabetic agent subject take antidiabetic agent least 12 week prior study entry ( Visit 1 ) never receive antidiabetic agent never &gt; 3 month time past ) . Age range 18 78 year inclusive . Male , nonfertile female female childbearing potential use medically approve birth control method . A nonfertile female define : post menopausal ( 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40mlU/m ) 6 week post bilateral oophorectomy without hysterectomy post hysterectomy sterilize tubal ligation . Written inform consent participate study . Ability comply study requirement . Pregnant lactate female A history type 1 diabetes , diabetes result pancreatic injury , secondary form diabetes , e.g. , Cushing´s syndrome acromegaly , acute metabolic diabetic complication ketoacidosis hyperosmolar state ( coma ) within past 6 month . Evidence significant diabetic complication , e.g. , symptomatic autonomic neuropathy gastroparesis . Acute infection wich may affect blood glucose control within 4 week prior visit 1 concurrent medical condition may interfere interpretation efficacy safety data study . Any follow within past 6 month : myocardial infarction ( MI ) ( visit one ECG reveal pattern consistent MI date event determine , patient enter study discretion investigator sponsor ) coronary artery bypass surgery percutaneous coronary intervention , unstable angina stroke . Congestive heart failure ( CHF ) require pharmacological treatment . Any following EGC abnormality ; `` Torsades de point '' , sustain clinically relevant ventricular tachycardia ventricular fibrillation , second degree AV block ( Mobitz 1 2 ) , third degree AV block , prolong QTc ( &gt; 500 msec ) Malignancy include leukemia lymphoma ( include basal cell skin cancer ) within last 5 year . Liver disease cirrhosis chronic active hepatitis . Donation one unit ( 500ml ) blood , significant blood loss equal least one unit blood within past 2 week blood transfusion within past 8 week . Chronic insulin ( &gt; 4 week treatment absence intercurrent illness ) within past 6 month . Chronic oral parenteral corticosteroid treatment ( &gt; 7 consecutive day treatment ) within 8 week prior visit 1 . Treatment growth hormone similar drug . Treatment class Ia , Ib Ic III antiarrhythmic . Patients already study sitagliptin another DPP 4 inhibitor . Use investigational drug visit 1 , within 30 day 5 halflives visit 1 . Any following significant laboratory abnormality : ALT , AST great 3 time upper limit normal range visit 1 . *clinically significant renal dysfunction indicate serum creatinine level &gt; equal 1,5mg/dl male , &gt; equal 1,4 mg/dl female , history abnormal creatinine clearance &lt; 60 ml/m2/24h clinically significant TSH value outside normal range visit 1 clinically significant laboratory abnormality , confirm repeated measurement , hyperglycemia , hyperinsulinemia , glycosuria visit 1. fasting triglyceride &gt; 700 mg / dl visit 1 . History active substance abuse ( include alcohol ) within past 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Sitagliptin</keyword>
	<keyword>Diets</keyword>
	<keyword>Diabetes type 2</keyword>
	<keyword>Näive patient</keyword>
</DOC>